SEC Form 4 · accession 0001209191-18-054429
VERTEX PHARMACEUTICALS INC / MA · VRTX
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sangeeta N. Bhatia
Director
Period of report
Oct 3, 2018
Accepted (ET)
Oct 5, 2018 · 5:28 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000875320
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Oct 3, 2018 | M | 2,118 | $125.71 | A | 6,997 | D | |
| Common Stock | Oct 3, 2018 | S | 2,118 | $192.13 | D | 4,879 | D | |
| Common Stock | Oct 3, 2018 | M | 4,700 | $126.68 | A | 9,579 | D | |
| Common Stock | Oct 3, 2018 | S | 4,700 | $192.13 | D | 4,879 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $125.71 | Oct 3, 2018 | M | 2,118 | D | — | May 31, 2027 | Common Stock | 2,118 | 3,177 | D |
| Stock Option (Right to Buy)F3 | $126.68 | Oct 3, 2018 | M | 4,700 | D | — | Jun 3, 2025 | Common Stock | 4,700 | 14,547 | D |
Explanation of responses
- F1Transaction made pursuant to Dr. Bhatia's company-approved trading plan under Rule 10b5-1.
- F2The option vests in 16 quarterly installments from 6/1/2017.
- F3The option vests in 16 quarterly installments from 6/4/2015.